Your AI-Trained Oncology Knowledge Connection!
John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.
Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the next steps for the prognostic model for atezolizumab (Tecentriq) in patients with urothelial carcinoma.
Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment landscape for patients with myeloproliferative neoplasms (MPNs).
Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses biomarker research in mantle cell lymphoma (MCL).
Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.
Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.
William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.
Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.
Heather Greene, a nurse practitioner at West Cancer Center, discusses the most common immune-related adverse events (AEs) in patients with non–small cell lung cancer (NSCLC), and whether or not these AEs vary between agents.
Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ongoing phase III studies in patients with multiple myeloma.
Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses EGFR tyrosine kinase inhibitors (TKIs) in lung cancer.
Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the development of immunotherapy in breast cancer.
Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).
Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses ongoing trials investigating chemoradiation for patients with head and neck cancer.
Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses pain management for patients with endometrial cancer.
R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma.
Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.
Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).
Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.
Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.
Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.
Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).
Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.
Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma.
David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in ovarian cancer.
Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.
Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of genetic testing in the treatment of patients with breast cancer.
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care® in Melanoma, discusses the side effect profile of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with melanoma.
Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer.
Laura M. Freedman, MD, assistant professor, director of Radiation Oncology, Sylvester Comprehensive Cancer Center, discusses the revised National Comprehensive Cancer Network (NCCN) guidelines for post-mastectomy radiation given in women who have pathologic T1 and T2 tumors and 1 to 3 positive lymph nodes.
